Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and <i>TP53</i> mutation status
Abstract
Abstract The MCL35 gene expression assay encompasses key risk features and stratified older patients with mantle cell lymphoma (MCL) using routine biopsies. In the SHINE trial, high-risk patients had poor outcomes despite adding ibrutinib to bendamustine-rituximab, highlighting an urgent need for novel strategies in high-risk MCL.
Article Details
Authors (9)
Ciara L. Freeman
7Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Srimathi Srinivasan
3Johnson & Johnson, Spring House, PA
Brendan Hodkinson
14Johnson & Johnson, Spring House, United States
Sanjay Deshpande
4Johnson & Johnson, Raritan, NJ
Todd Henninger
Johnson & Johnson, Raritan, NJ
Merrill Boyle
1Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, BC, Canada
Michael L. Wang
14The University of Texas MD Anderson Cancer Center, Houston, TX
Martin Dreyling
LMU Hospital, Munich, Germany
David W. Scott
5Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada